MME Dominique HUBERT

Rhumatologue

RPPS 10000296730

📊 Reconnaissance scientifique : 2/100📝 3 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Profil synthétique

IA · 20/05/2026

MME Dominique HUBERT est une rhumatologue avec des publications dans le domaine de la rhumatologie et des recherches sur les maladies osseuses. Ses travaux de recherche portent sur des sujets variés, notamment la pharmacovigilance et l'épidémiologie. Elle a un h-index de 2 selon OpenAlex, basé sur 3 publications.

Expertises présumées

Essais cliniques en rhumatologie
Pharmacovigilance en rhumatologie
Épidémiologie des maladies rhumatismales
Myélome multiple
Dégradation des protéines
Intelligence artificielle en rhumatologie
Recherche en vraie vie (RWE) en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Médecin engagé dans la recherche académique — 3 publications référencées dans les bases scientifiques internationales, contribuant aux travaux sur protease and inhibitor mechanisms et multiple myeloma research and treatments.

Thématiques principales

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole

Antimicrobial agents and chemotherapy · 2012

📚 144 citations🎯 RCR 5.65Top 6% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ABSTRACT Aspergillus fumigatus is the most frequent fungus found in the sputum of cystic fibrosis (CF) subjects. Itraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects. We hypothesized that A. fumigatus isolates in the sputum of CF subjects with previous exposure to itraconazole was associated with higher prevalence of azole resistance. From June 2010 to April 2011, sputum samples from adult CF subjects at Cochin University Hospital (France) were examined systematically for the detection of A. fumigatus . MICs of A. fumigatus isolates against azoles were screened using Etest, and reduced susceptibility to azoles was confirmed using the CLSI broth microdilution method. A. fumigatus was isolated from the sputum of 131/249 (52.6%) adult CF subjects, and 47/131 (35.9%) subjects had received previous treatment with itraconazole. Reduced A. fumigatus susceptibility to itraconazole (MIC, ≥2 mg/liter) was confirmed in 6/131 (4.6%) subjects. All 6 isolates also had reduced susceptibility to posaconazole (MIC, ≥0.5 mg/liter), and 3/6 isolates had reduced susceptibility to voriconazole (MIC, ≥2 mg/liter). Mutations in the cyp51A gene were detected at positions previously implicated to cause resistance in 5 isolates. Azole-resistant A. fumigatus isolates were found in 5/25 (20%) subjects exposed to itraconazole within the previous 3 years. High rates of azole-resistant A. fumigatus isolates were present in adult CF subjects and were associated with recent itraconazole exposure. Although the clinical implications of these findings will require further studies, the cautious use of itraconazole in adult CF subjects can be recommended.

Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis

American journal of respiratory and critical care medicine · 2020

📚 105 citations🎯 RCR 6.55Top 5% NIH🩺 Clinique

Lire l'abstract Crossref ↓

Abstract Rationale Lumacaftor–ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination recently approved for patients with cystic fibrosis (CF) homozygous for the Phe508del mutation. Objectives To evaluate the safety and effectiveness of lumacaftor–ivacaftor in adolescents (≥12 yr) and adults (≥18 yr) in a real-life postapproval setting. Methods The study was conducted in the 47 CF reference centers in France. All patients who initiated lumacaftor–ivacaftor from January 1 to December 31, 2016, were eligible. Patients were evaluated for lumacaftor–ivacaftor safety and effectiveness over the first year of treatment following the French CF Learning Society’s recommendations. Measurements and Main Results Among the 845 patients (292 adolescents and 553 adults) who initiated lumacaftor–ivacaftor, 18.2% (154 patients) discontinued treatment, often owing to respiratory (48.1%, 74 patients) or nonrespiratory (27.9%, 43 patients) adverse events. In multivariable logistic regression, factors associated with increased rates of discontinuation included adult age group, percent predicted FEV1 (ppFEV1) less than 40%, and numbers of intravenous antibiotic courses during the year before lumacaftor–ivacaftor initiation. Patients with continuous exposure to lumacaftor–ivacaftor showed an absolute increase in ppFEV1 (+3.67%), an increase in body mass index (+0.73 kg/m2), and a decrease in intravenous antibiotic courses by 35%. Patients who discontinued treatment had significant decrease in ppFEV1, without improvement in body mass index or decrease in intravenous antibiotic courses. Conclusions Lumacaftor–ivacaftor was associated with improvement in lung disease and nutritional status in patients who tolerated treatment. Adults who discontinued lumacaftor–ivacaftor, often owing to adverse events, were found at high risk of clinical deterioration.

Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2013

📚 94 citations🎯 RCR 3.53Top 13% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME Dominique HUBERT

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (2)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal38

Essai clinique4

Vraie vie / RWE4

Pharmacovigilance2

Case report / série1

Épidémiologie & registres1

IA en rhumatologie1

Pédiatrie1

Qualité de vie / PROMs1

Datasets & protocoles partagés

Partager cette fiche